<PAPER><mode2 name='PMC3617973' hasDoc='yes' version='597'></mode2><article xmlns:mml='http://www.w3.org/1998/Math/MathML' xmlns:xlink='http://www.w3.org/1999/xlink' article-type='research-article'><front><journal-meta><journal-id journal-id-type='nlm-ta'>Dement Geriatr Cogn Dis Extra</journal-id><journal-id journal-id-type='iso-abbrev'>Dement Geriatr Cogn Dis Extra</journal-id><journal-id journal-id-type='publisher-id'>DEE</journal-id><journal-title-group><journal-title>Dementia and Geriatric Cognitive Disorders EXTRA</journal-title></journal-title-group><issn pub-type='ppub'>1664-5464</issn><issn pub-type='epub'>1664-5464</issn><publisher><publisher-name>S. Karger AG</publisher-name><publisher-loc>Allschwilerstrasse 10, P.O. Box · Postfach · Case postale, CH–4009, Basel, Switzerland · Schweiz · Suisse, Phone: +41 61 306 11 11, Fax: +41 61 306 12 34, karger@karger.ch</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type='pmcid'>3617973</article-id><article-id pub-id-type='doi'>10.1159/000345279</article-id><article-id pub-id-type='publisher-id'>dee-0003-0048</article-id><article-categories><subj-group subj-group-type='heading'><subject>Original Research Article</subject></subj-group></article-categories><title-group><article-title><s sid='1'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Goa1' type='Goa'></CoreSc1>Persistence of Cholinesterase Inhibitor Treatment in Dementia: Insights from a Naturalistic Study</s></article-title></title-group><contrib-group><contrib contrib-type='author'><name><surname>Olazarán</surname><given-names>Javier</given-names></name><xref rid='aff1' ref-type='aff'><sup>a</sup></xref><xref rid='aff2' ref-type='aff'><sup>b</sup></xref><xref rid='cor1' ref-type='corresp'>*</xref></contrib><contrib contrib-type='author'><name><surname>Navarro</surname><given-names>Eloísa</given-names></name><xref rid='aff3' ref-type='aff'><sup>c</sup></xref></contrib><contrib contrib-type='author'><name><surname>Rojo</surname><given-names>José Manuel</given-names></name><xref rid='aff4' ref-type='aff'><sup>d</sup></xref></contrib></contrib-group><aff id='aff1'><sup>a</sup>Hermanos Sangro Specialties Clinic, Service of Neurology, Gregorio Marañón University Hospital, Madrid, Spain</aff><aff id='aff2'><sup>b</sup>Alzheimer Disease Research Unit, Alzheimer Center Reina Sofía Foundation, CIEN Foundation, Carlos III Institute of Health, Madrid, Spain</aff><aff id='aff3'><sup>c</sup>Vicente Soldevilla Specialties Clinic, Service of Neurology, Infanta Leonor Hospital, Madrid, Spain</aff><aff id='aff4'><sup>d</sup>Superior Council of Scientific Research, Madrid, Spain</aff><author-notes><corresp id='cor1'>*Javier Olazarán, CEP Hermanos Sangro, Avda. de Peña Prieta 4, ES-28038 Madrid (Spain), E-Mail <email>javier@mariawolff.es</email></corresp></author-notes><pub-date pub-type='collection'><season>Jan-Dec</season><year>2013</year></pub-date><pub-date pub-type='epub'><day>1</day><month>3</month><year>2013</year></pub-date><pub-date pub-type='pmc-release'><day>1</day><month>3</month><year>2013</year></pub-date><volume>3</volume><issue>1</issue><fpage>48</fpage><lpage>59</lpage><permissions><copyright-statement>Copyright © 2013 by S. Karger AG, Basel</copyright-statement><copyright-year>2013</copyright-year><license license-type='open-access' xlink:href='http://creativecommons.org/licenses/by-nc-nd/3.0/'><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial-No-Derivative-Works License (<ext-link ext-link-type='uri' xlink:href='http://creativecommons.org/licenses/by-nc-nd/3.0/'>http://creativecommons.org/licenses/by-nc-nd/3.0/</ext-link>). Users may download, print and share this work on the Internet for noncommercial purposes only, provided the original work is properly cited, and a link to the original work on <ext-link ext-link-type='uri' xlink:href='http://www.karger.com'>http://www.karger.com</ext-link> and the terms of this license are included in any shared versions.</license-p></license></permissions><abstract><sec><title>Background</title><p><s sid='2'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Cholinesterase inhibitors (ChEI) are widely used in dementia, but there is a lack of practice guidelines in case of intolerance or absence of perceived effect.</s></p></sec><sec><title>Methods</title><p><s sid='3'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1>Two hundred and forty patients (mean age 77 years, SD 6.3, 66% female) with Alzheimer's disease or Lewy body dementia were prescribed a ChEI and evaluated annually under conditions of standard practice.</s><s sid='4'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1> Of these, 152 patients maintained, 36 switched, and 52 abandoned ChEI treatment.</s></p></sec><sec><title>Results</title><p><s sid='5'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>Less behavioural disturbance and less cognitive deterioration were observed, respectively, at the 3- and 4-year follow-up assessments in the patients who maintained the first prescribed ChEI (p &lt; 0.05).</s><s sid='6'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Cognitive benefits were reinforced in the patients who experienced some adverse event, but no benefits were observed when the patient or caregiver did not perceive an effect.</s></p></sec><sec><title>Conclusions</title><p><s sid='7'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1>Maintenance of the first prescribed ChEI was supported when some benefit was perceived by the patient or caregiver, even in cases of nonserious adverse events.</s></p></sec></abstract><kwd-group><title>Key Words </title><kwd>Alzheimer's disease</kwd><kwd>Cholinesterase inhibitors</kwd><kwd>Lewy body dementia</kwd><kwd>Treatment persistence </kwd></kwd-group><counts><fig-count count='3'></fig-count><table-count count='3'></table-count><ref-count count='18'></ref-count><page-count count='12'></page-count></counts></article-meta></front><body><sec id='sec1_1'><title>Introduction</title><p><s sid='8'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Randomized controlled trials (RCT) of cholinesterase inhibitors (ChEI) demonstrated small but sufficient efficacy, leading them to become accepted as the primary pharmacological treatment of Alzheimer's disease (AD) – with or without associated cerebrovascular disease – and Lewy body dementia [<xref rid='B1' ref-type='bibr'>1</xref>,<xref rid='B2' ref-type='bibr'>2</xref>].</s><s sid='9'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> However, most RCT were of short duration (i.e. 12-24 weeks) and, after two decades of widespread use, there are still important unsolved questions regarding long-term efficacy and safety of these medications.</s><s sid='10'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> In addition, the results obtained from RCT should not necessarily be generalized for standard clinical practice [<xref rid='B3' ref-type='bibr'>3</xref>].</s></p><p><s sid='11'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>The conditions of standard practice are quite different from RCT.</s><s sid='12'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> In standard practice, patients with comorbidity, physical frailty, and combined/less certain aetiologies are more frequent.</s><s sid='13'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> In addition, physicians choose medications that best match patient and caregiver characteristics, with considerable space for personal experience and preferences [<xref rid='B4' ref-type='bibr'>4</xref>].</s><s sid='14'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Regarding ChEI, a potentially relevant question, which is clearly open to the physician's subjectivity, is the issue of whether to switch or stay on the first prescribed ChEI in case of intolerance or absence of a clinically apparent effect.</s><s sid='15'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> In a scenario of nonserious intolerance and good physical health, a trial with a second ChEI seems reasonable.</s><s sid='16'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> However, when there is good tolerability but lack of perceived effect, continuation, discontinuation, and switch seem equally arguable.</s><s sid='17'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Mot1' type='Mot'></CoreSc1> Clearly, more research is needed to support such a decision given the potential consequences in terms of safety, efficacy, and cost.</s></p><p><s sid='18'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Goa1' type='Goa'></CoreSc1>We conducted a naturalistic study (i.e. the ChEI Study) to primarily describe and compare the tolerability of, and the response to, the three most used ChEI (i.e. donepezil, rivastigmine, and galantamine) in patients with cognitive deterioration of any aetiology.</s><s sid='19'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Goa1' type='Goa'></CoreSc1> In the present article, we focused on data regarding persistence and change of ChEI in those patients with a final diagnosis of AD or Lewy body dementia.</s><s sid='20'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Goa1' type='Goa'></CoreSc1> The aim was to describe the circumstances associated with (and gain insight on the potential consequences of) maintaining, switching, or abandoning ChEI treatment in those patients.</s></p></sec><sec sec-type='methods' id='sec1_2'><title>Methods</title><sec id='sec2_1'><title>Setting and Study Process</title><p><s sid='21'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>The ChEI Study was designed and conducted in two neurology clinics that serve two low-middle class areas in the southern suburbs of Madrid.</s><s sid='22'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Most patients were referred by their family physicians.</s><s sid='23'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Patients were systematically and prospectively recruited from January 1, 2002 to May 31, 2006 by the authors, two senior neurologists with special dedication to dementia.</s><s sid='24'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> At the beginning of recruitment, the three most used ChEI (i.e. donepezil, rivastigmine, and galantamine) were available (galantamine, the last ChEI to appear, was launched in Spain on September 10, 2001).</s><s sid='25'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The inclusion criteria of the ChEI Study were the following: (1) the patient attended the clinic accompanied by a reliable caregiver, (2) cognitive impairment of any aetiology was diagnosed and documented, (3) a ChEI was prescribed for the first time to that patient by the study neurologist, and (4) a 1-year follow-up visit was performed.</s></p><p><s sid='26'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>All the included patients received a complete medical history that comprised medical history, physical and neurological exam, Mini-Mental State Examination (MMSE) [<xref rid='B5' ref-type='bibr'>5</xref>], and Clinical Dementia Rating Scale (CDR) [<xref rid='B6' ref-type='bibr'>6</xref>].</s><s sid='27'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> That visit was considered the baseline visit for the ChEI Study.</s><s sid='28'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> When not available, a structural brain imaging study (i.e. CT scan or MRI) and blood determinations (including blood count, glucose, creatinine, transaminases, calcium, thyroid stimulating hormone, B<sub>12</sub>, and folate) were ordered [<xref rid='B7' ref-type='bibr'>7</xref>].</s><s sid='29'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> ChEI was prescribed at the baseline visit or 1-3 months later (when tests were ordered).</s><s sid='30'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Since the inclusion day was the day of ChEI prescription and a 1-year follow-up visit was required for inclusion, baseline data were retrospectively collected.</s></p><p><s sid='31'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>ChEI were prescribed according to patient and caregiver characteristics.</s><s sid='32'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Due to the simplest titration, donepezil was chosen when there were not many assurances that the patient and the caregiver would comply with the prescribed medication.</s><s sid='33'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Rivastigmine was preferred in case of parkinsonism, liver disease, or a high risk of drug interactions.</s><s sid='34'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Impaired sleep-wake rhythm and mixed dementia were reasons to choose galantamine [<xref rid='B4' ref-type='bibr'>4</xref>].</s><s sid='35'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> In case of tolerance and good health, the maximum dose of ChEI was tried, usually within a period of time longer than the period recommended by manufacturers.</s><s sid='36'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Yearly follow-up visits were scheduled plus additional visits as the clinical situation indicated.</s><s sid='37'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Dementia diagnosis and aetiology were established at the baseline visit and those diagnoses were reconsidered at every annual visit.</s></p><p><s sid='38'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>The present study was designed once the database of the ChEI Study was completed and closed.</s><s sid='39'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1> For the present study, only those patients with a final diagnosis of AD [<xref rid='B8' ref-type='bibr'>8</xref>] or Lewy body dementia [<xref rid='B9' ref-type='bibr'>9</xref>], in the presence or not of a vascular component, were selected.</s><s sid='40'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Since all the procedures were in accordance with standard practice, no study-specific consent was required.</s><s sid='41'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The present study was approved by the ethics committee of Gregorio Marañón University Hospital.</s></p></sec><sec id='sec2_2'><title>Outcome Variables</title><p><s sid='42'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>The variables listed below, which were conducted at baseline and annually by the study neurologists during standard practice, were utilized as outcome variables.</s></p><p><s sid='43'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1><italic>Mini-Mental State Examination.</italic> This test offers a feasible and universal measure of general cognition for standard practice, with scores ranging from 0 (worse cognitive state) to 30 (best cognitive state) [<xref rid='B5' ref-type='bibr'>5</xref>].</s></p><p><s sid='44'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1><italic>Functional Assessment Staging Scale.</italic> This instrument depicts the predictable functional losses of a typical AD patient [<xref rid='B10' ref-type='bibr'>10</xref>].</s><s sid='45'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> It has been used previously as a measure of functional response to drug treatment in AD [<xref rid='B11' ref-type='bibr'>11</xref>].</s><s sid='46'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The possible score ranges from 1 (lack of functional symptoms) to 16 (vegetative state).</s></p><p><s sid='47'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1><italic>Behavioural and Psychological Symptoms of Dementia.</italic> During visits, the neurologist elicited information from both the patient and caregiver regarding the following potential behavioural and psychological symptoms of dementia (BPSD): delusions, hallucinations, aggressive behaviour, dysphoria, anxiety, apathy, irritability, aberrant motor behaviour, appetite and eating disorders, euphoria, and disinhibition.</s><s sid='48'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Those BPSD categories and their corresponding definitions were taken from the Neuropsychiatric Inventory [<xref rid='B12' ref-type='bibr'>12</xref>], although this instrument was not formally administered.</s><s sid='49'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The BPSD were codified as present or absent.</s><s sid='50'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Symptoms were present if they appeared any time from the beginning of cognitive symptoms (baseline visit) or from the last visit (annual follow-up visits).</s><s sid='51'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Those BPSD that were completely controlled with medication were codified as absent.</s><s sid='52'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Both the total number of BPSD and frequency of the different BPSD were analysed.</s></p><p><s sid='53'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1><italic>Perceived Effect.</italic> This was defined as cognitive, functional, affective, or behavioural stabilization or improvement, either transitorily or permanently, as referred to by the patient or caregiver during the study follow-up visits.</s><s sid='54'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The effect was usually referred to in the first 1-3 months after ChEI initiation or dose increase.</s></p><p><s sid='55'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1><italic>Safety and Tolerability Measures.</italic> All the potential events related to tolerability and safety of the ChEI were requested and registered at every follow-up visit.</s><s sid='56'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Caregivers were specifically asked about number of falls, falls with fractures, episodes of loss of consciousness, use of medications, emergency room visits, and hospitalizations.</s></p></sec><sec id='sec2_3'><title>Statistical Analysis</title><p><s sid='57'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>Descriptive statistics were used to present patient and caregiver demographic and clinical characteristics and also to present tolerability and safety data.</s><s sid='58'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Treatment persistence, change, and abandonment were defined according to the longitudinal data available at the last visit.</s><s sid='59'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Persistence on ChEI was defined as maintenance of the initially prescribed ChEI throughout the study period, with neither gaps nor changes of treatment.</s><s sid='60'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Change of ChEI was defined as a switch to another ChEI, and abandonment was defined as a lack of any ChEI at the last available visit, independent of ChEI change.</s></p><p><s sid='61'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>Patient and caregiver differences according to study completion, first prescribed ChEI, and ChEI persistence were analysed at study inception by means of t test and χ<sup>2</sup> test.</s><s sid='62'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The evolution of cognitive, functional, and behavioural outcomes in patients who persisted on first ChEI, in patients who were switched, and in patients who abandoned ChEI treatment were analysed using repeated measures analysis of covariance adjusted for age and number of chronic diseases.</s><s sid='63'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Separate models were elaborated for every annual follow-up assessment, using the baseline assessment as the reference.</s><s sid='64'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Analyses were conducted for the complete sample of patients and also, separately, for the subsamples of patients who experienced some adverse event and for whom treatment effect was not perceived (adverse events and perceived effect were referred to the first prescribed ChEI only).</s><s sid='65'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> To mitigate the effect of study losses, both observed cases and last observation carried forward (LOCF) analyses were systematically conducted.</s><s sid='66'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The MMSE, Functional Assessment Staging Scale, and number of BPSD were considered primary outcomes.</s><s sid='67'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Because of the potential relevance for clinical practice, post hoc analyses were conducted in the complete sample to ascertain which behavioural domains benefitted from ChEI persistence and the possible repercussion of those behavioural benefits for antipsychotic prescription.</s><s sid='68'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Since this was an exploratory study with no previously established hypotheses, multiple comparison adjustment was not conducted [<xref rid='B13' ref-type='bibr'>13</xref>].</s><s sid='69'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Statistical analyses were performed using SPSS version 16.0 software (SPSS, Chicago, Ill., USA).</s></p></sec></sec><sec sec-type='results' id='sec1_3'><title>Results</title><p><s sid='70'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1>The ChEI Study cohort comprised 270 patients, of whom 240 (89%) met inclusion criteria for the present investigation.</s><s sid='71'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1> Reasons for exclusion were: no cognitive impairment (1 patient), vascular dementia (4 patients), degenerative aetiology different from AD or Lewy body disease (3 patients), secondary dementia (6 patients), and uncertain aetiology for cognitive impairment or dementia (16 patients).</s><s sid='72'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1> At the baseline assessment, 3 of the 240 included patients (1%) were institutionalized.</s><s sid='73'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> There was important attrition throughout the study.</s><s sid='74'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> As per inclusion criteria, all the patients were evaluated at the 1-year follow-up visit.</s><s sid='75'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1> In addition, 230 patients (95.8%), 194 patients (80.8%), 161 patients (67.1%), and 136 patients (56.7%) could be evaluated in at least one primary outcome measure at the 2-, 3-, 4-, and 5-year follow-up visits, respectively.</s><s sid='76'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Patients who did not complete the 5-year follow-up visit tended to be older (mean age 78.1 years, SD 6.8 vs. 76.5 years, SD 6.8, p = 0.061), tended to be more frequently diagnosed with Lewy body dementia (16.3 vs. 8.8%, p = 0.076), and received neuroleptic treatment at the baseline assessment more frequently (9.7 vs. 2.9%, p = 0.0278; all other p values for differences between noncompleters and completers &gt;0.10, data not shown).</s><s sid='77'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Persistence, change, or abandonment of ChEI treatment did not influence study loss or death (table <xref rid='T1' ref-type='table'>1</xref>).</s></p><p><s sid='78'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1>The mean age of the total sample was 77.0 years (SD 6.3, range 51-89) and 66% of the patients were female.</s><s sid='79'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The educational achievement was as follows: illiterate (16%), incomplete primary studies (45%), primary studies (34%), and superior studies (4%).</s><s sid='80'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Most patients were in the mild stage of dementia according to the CDR: CDR 0.5 (21%), CDR 1 (69%), CDR 2 (8%), and CDR 3 (2%).</s><s sid='81'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1> Caregivers were more frequently female (70%) and lived with the patient (68%).</s><s sid='82'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1> The family link was as follows: daughter or son (50%), spouse (40%), sister or brother (4%), and other (6%).</s></p><p><s sid='83'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>Donepezil was the most frequently first prescribed ChEI (49.2%) followed by galantamine (28.3%) and rivastigmine (22.5%).</s><s sid='84'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Donepezil was more frequently prescribed for patients with probable AD, whereas galantamine and rivastigmine were more frequently prescribed for, respectively, patients with AD with a vascular component and patients with Lewy body disease (p &lt; 0.05).</s><s sid='85'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Galantamine was also more frequently initiated in case of hypertension, whereas donepezil prescription was associated with an inferior educational achievement (p &lt; 0.05).</s><s sid='86'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Rivastigmine prescription was associated with more cognitive deterioration, more apathy, and a higher number of physical comorbidities and medications at baseline assessment (p &lt; 0.05, all other p values for differences between groups according to the first prescribed ChEI &gt;0.05, data not shown).</s></p><p><s sid='87'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>Most patients (63.3%) maintained treatment with the first prescribed ChEI in the last study visit.</s><s sid='88'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Reasons for ChEI switch or abandonment were intolerance (61.6%), lack of perceived efficacy (26.7%), both intolerance and lack of efficacy (7.0%), and other reasons (4.7%).</s><s sid='89'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Patient and caregiver features according to ChEI persistence are presented in table <xref rid='T2' ref-type='table'>2</xref>.</s><s sid='90'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Patients who were switched to other ChEI were younger in comparison to patients who abandoned ChEI treatment.</s><s sid='91'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> In addition, patients who changed ChEI received antidepressants at baseline assessment more frequently, whereas patients who persisted on the first ChEI displayed white matter changes more frequently [<xref rid='B14' ref-type='bibr'>14</xref>] (p &lt; 0.05).</s></p><p><s sid='92'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>A response to the first prescribed ChEI (either stabilization or improvement) was reported by 45.8% of patients or caregivers, but some intolerance or adverse event was also recorded in 54.0% of the total sample.</s><s sid='93'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Persistence on the first prescribed ChEI was clearly associated with better tolerability and perceived response, whereas bad tolerability seemed to influence the decision of abandoning ChEI, rather than changing ChEI (66.0 vs. 55.6%, p = 0.142; table <xref rid='T3' ref-type='table'>3</xref>).</s></p><p><s sid='94'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>Less behavioural disturbance and less cognitive deterioration were observed, respectively, at the 3- and 4-year follow-up assessments in those patients who persisted on the first prescribed ChEI (p &lt; 0.05) and a trend of less functional deterioration was also documented at the 4-year follow-up visit in those patients (p = 0.057), but statistical significance was not attained in the corresponding LOCF analyses (fig <xref rid='F1' ref-type='fig'>1</xref>).</s><s sid='95'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Post hoc analyses were conducted to ascertain which behavioural domains were improved at the 3-year assessment.</s><s sid='96'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Statistically significant differences were only found for prevalence of delusions (10.9, 20.0, and 40.0%, respectively, for those patients who persisted, changed, and abandoned ChEI treatment, p &lt; 0.0005; all other p values &gt;0.05, data not shown).</s><s sid='97'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> To gain further insight on the effect of ChEI persistence on affective and behavioural disturbance, additional post hoc analyses were conducted on the prevalence of psychotropic medication prescription at the 3- and 4-year follow-up visits.</s><s sid='98'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> A trend of less frequent use of neuroleptics was found at the 3-year follow-up visit in those patients who persisted on the first prescribed ChEI (12.7, 26.7, and 24.4%, respectively, for those patients who persisted, changed, or abandoned ChEI treatment; p = 0.078).</s><s sid='99'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The corresponding figures at the 4-year follow-up visit were 13.5, 20.0, and 21.1% (p = 0.494).</s><s sid='100'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Other differences or trends in use of psychotropic medications were not found (all p values &gt;0.10, data not shown).</s></p><p><s sid='101'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1>Cognitive and functional results in the subsample of patients who experienced some adverse event were similar to the results observed in the complete sample, with even slightly larger long-term benefits in the patients who persisted on the first prescribed ChEI (fig. <xref rid='F2' ref-type='fig'>2</xref>), but between-group differences were not detected regarding behavioural evolution.</s><s sid='102'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> As for the subsample of patients who had no perceived ChEI treatment effect, worse functional evolution was detected at the 1-year follow-up visit in those patients who persisted on the first ChEI, but less BPSD were also detected for those patients at the 3-year follow-up visit.</s><s sid='103'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The cognitive evolution of these patients was similar, no matter if they maintained, changed, or abandoned ChEI treatment (fig. <xref rid='F3' ref-type='fig'>3</xref>).</s></p></sec><sec sec-type='discussion' id='sec1_4'><title>Discussion</title><p><s sid='104'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Goa1' type='Goa'></CoreSc1>The causes and effects of ChEI treatment persistence were retrospectively explored in the database of a 5-year observational study that was conducted during standard clinical practice.</s><s sid='105'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> For the study physicians, the primary aim when prescribing a ChEI was to attain the best balance of clinical benefit, tolerability, safety, and caregiver convenience.</s><s sid='106'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> In that scenario, a more favourable cognitive, functional, and behavioural outcome was observed in those patients who persisted on the first prescribed ChEI.</s><s sid='107'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> Those results were reinforced in the subsample of patients who experienced ChEI intolerance, but disappeared in the subsample of patients who, according to patient and caregiver, did not experience positive effect.</s></p><p><s sid='108'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>Treatment persistence did not depend on the prescribed ChEI.</s><s sid='109'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> In this regard, a trend of more favourable outcome for donepezil was noted (table <xref rid='T2' ref-type='table'>2</xref>), but it should be said that, at study inception, neither galantamine extended-release capsules nor rivastigmine patches were available.</s><s sid='110'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Hence, under quite different patient and caregiver circumstances and once the ChEI that best fit the particular patient and caregiver dyad was chosen, persistence on the different ChEI was similar.</s><s sid='111'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> This observation reinforces the view that results from clinical trials do not necessarily generalize to clinical practice [<xref rid='B15' ref-type='bibr'>15</xref>], with an important role left to physicians to optimize ChEI effects.</s></p><p><s sid='112'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>What other lessons can we extract for standard practice?</s><s sid='113'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> We believe that physicians should be proactive when discussing ChEI treatment with otherwise healthy AD or Lewy body dementia patients and caregivers, in light of the consistent and durable positive results observed in the domains of cognition, function, and behaviour.</s><s sid='114'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> In addition, the presence of concomitant cerebrovascular disease, on the basis of clinical or neuroimaging data, should not hinder a proactive attitude towards ChEI treatment.</s><s sid='115'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> It also seems clear that the first ChEI inhibitor should be maintained if some positive response is perceived, even in case of some intolerance, provided there are no important safety concerns.</s><s sid='116'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> A titration slower than usual could be of help in such cases.</s></p><p><s sid='117'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>When important intolerance is experienced during the early titration phase, with no place for evaluating a potential clinical benefit, a trial of a second ChEI seems reasonable after complete resolution of side effects and provided there is no serious risk.</s><s sid='118'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> However, what should one do when there is no perceived effect once the maximal dose is achieved and well tolerated?</s><s sid='119'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> A possible response to a second ChEI, after failure of the initial ChEI, has not been extensively or rigorously investigated.</s><s sid='120'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Improvement with a second ChEI has been described in open trials, but those results could have been influenced by expectation bias [<xref rid='B16' ref-type='bibr'>16</xref>,<xref rid='B17' ref-type='bibr'>17</xref>].</s><s sid='121'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> The results from the present investigation suggest that a lack of response to ChEI could be a class effect, with little space for trying different ChEI.</s><s sid='122'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Mot1' type='Mot'></CoreSc1> Identifying predictors of ChEI response remains an important but elusive issue [<xref rid='B18' ref-type='bibr'>18</xref>].</s><s sid='123'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Mot1' type='Mot'></CoreSc1> Patients who did not respond to ChEI could be good candidates for trials of new medications, where no treated patients would be preferable.</s></p><p><s sid='124'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>The present study has strengths and limitations.</s><s sid='125'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> A representative sample of patients was administered a ChEI on an individual basis, without financial restrictions, and followed for over 5 years.</s><s sid='126'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> However, most significant results emerged in the long term, when there was important study attrition.</s><s sid='127'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> In addition, the study groups were not fully comparable at inception.</s><s sid='128'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Patients who abandoned ChEI treatment were older and tended to have more chronic diseases (table <xref rid='T2' ref-type='table'>2</xref>), and patients who were lost to follow-up also tended to be older.</s><s sid='129'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> Hence, caution should be taken before generalizing the present results to the physically frail old population.</s></p><p><s sid='130'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>It could also be speculated that our patients who maintained ChEI presented with a slower cognitive and functional deterioration that influenced the physician's decision of staying on the initial ChEI.</s><s sid='131'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> This explanation cannot be definitively ruled out given the observational design, but it seems unlikely to the authors for two reasons.</s><s sid='132'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> First, disease duration and severity of dementia before treatment were comparable in the three study groups (table <xref rid='T2' ref-type='table'>2</xref>).</s><s sid='133'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> And second, a better response to ChEI was reported in patients with more rapid cognitive deterioration [<xref rid='B18' ref-type='bibr'>18</xref>].</s></p><p><s sid='134'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1>In conclusion, ChEI seem to be effective and safe for the long-term treatment of Alzheimer's and Lewy body dementia, even in the presence of nonserious adverse events.</s><s sid='135'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> A simple perception of benefit by the patient or caregiver was a good indicator of objective clinical response and could be of help in the decision of maintaining ChEI treatment or not.</s><s sid='136'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> Final decisions regarding treatment should always be taken after considering the individual characteristics of the patient and caregiver, including their personal opinions and values.</s></p></sec><sec id='sec1_5'><title>Disclosure Statement</title><p>Dr. Olazarán has received research support from Eisai. He has also received speaker's honoraria from Grunenthal, Esteve, Pfizer, Novartis, Janssen, and Lündbeck. Dr. Navarro has received speaker's honoraria from Esteve, Pfizer, Novartis, Grunenthal, and Lündbeck. Dr. Rojo declares no conflict of interest.</p></sec></body><back><ref-list><title>References</title><ref id='B1'><label>1</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Raina</surname><given-names>P</given-names></name><name><surname>Santaguida</surname><given-names>P</given-names></name><name><surname>Ismaila</surname><given-names>A</given-names></name><name><surname>Patterson</surname><given-names>C</given-names></name><name><surname>Cowan</surname><given-names>D</given-names></name><name><surname>Levine</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline</article-title><source>Ann Intern Med</source><year>2008</year><volume>148</volume><fpage>379</fpage><lpage>397</lpage><pub-id pub-id-type='pmid'>18316756</pub-id></element-citation></ref><ref id='B2'><label>2</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Howard</surname><given-names>R</given-names></name><name><surname>McShane</surname><given-names>R</given-names></name><name><surname>Lindesay</surname><given-names>J</given-names></name><name><surname>Ritchie</surname><given-names>C</given-names></name><name><surname>Baldwin</surname><given-names>A</given-names></name><name><surname>Barber</surname><given-names>R</given-names></name><etal></etal></person-group><article-title>Donepezil and memantine for moderate-to-severe Alzheimer's disease</article-title><source>N Engl J Med</source><year>2012</year><volume>366</volume><fpage>893</fpage><lpage>903</lpage><pub-id pub-id-type='pmid'>22397651</pub-id></element-citation></ref><ref id='B3'><label>3</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Pavlik</surname><given-names>VN</given-names></name><name><surname>Doody</surname><given-names>RS</given-names></name></person-group><article-title>Progress in understanding variability in cognitive responses to cholinesterase inhibitor treatment</article-title><source>Alzheimers Res Ther</source><year>2011</year><volume>3</volume><fpage>30</fpage><pub-id pub-id-type='pmid'>21999183</pub-id></element-citation></ref><ref id='B4'><label>4</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Gil</surname><given-names>P</given-names></name><name><surname>Ayuso</surname><given-names>JL</given-names></name><name><surname>Marey</surname><given-names>JM</given-names></name><name><surname>Antón</surname><given-names>M</given-names></name><name><surname>Quilo</surname><given-names>CG</given-names></name></person-group><article-title>Variability in the diagnosis and management of patients with Alzheimer's disease and cerebrovascular disease: results from the GALATEA multicentre, observational study</article-title><source>Clin Drug Investig</source><year>2008</year><volume>28</volume><fpage>429</fpage><lpage>437</lpage></element-citation></ref><ref id='B5'><label>5</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Folstein</surname><given-names>MF</given-names></name><name><surname>Folstein</surname><given-names>SE</given-names></name><name><surname>McHugh</surname><given-names>PR</given-names></name></person-group><article-title>Mini-mental state: a practical method for grading the cognitive state of patients for the clinician</article-title><source>J Psychiatr Res</source><year>1975</year><volume>12</volume><fpage>189</fpage><lpage>198</lpage><pub-id pub-id-type='pmid'>1202204</pub-id></element-citation></ref><ref id='B6'><label>6</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Hughes</surname><given-names>CP</given-names></name><name><surname>Berg</surname><given-names>L</given-names></name><name><surname>Danziger</surname><given-names>WL</given-names></name><name><surname>Coben</surname><given-names>LA</given-names></name><name><surname>Martin</surname><given-names>RL</given-names></name></person-group><article-title>A new clinical scale for the staging of dementia</article-title><source>Br J Psychiatry</source><year>1982</year><volume>140</volume><fpage>566</fpage><lpage>572</lpage><pub-id pub-id-type='pmid'>7104545</pub-id></element-citation></ref><ref id='B7'><label>7</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Feldman</surname><given-names>HH</given-names></name><name><surname>Jacova</surname><given-names>C</given-names></name><name><surname>Robillard</surname><given-names>A</given-names></name><name><surname>Garcia</surname><given-names>A</given-names></name><name><surname>Chow</surname><given-names>T</given-names></name><name><surname>Borrie</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Diagnosis and treatment of dementia: 2. Diagnosis</article-title><source>CMAJ</source><year>2008</year><volume>178</volume><fpage>825</fpage><lpage>836</lpage><pub-id pub-id-type='pmid'>18362376</pub-id></element-citation></ref><ref id='B8'><label>8</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>McKhann</surname><given-names>G</given-names></name><name><surname>Drachman</surname><given-names>D</given-names></name><name><surname>Folstein</surname><given-names>M</given-names></name><name><surname>Katzman</surname><given-names>R</given-names></name><name><surname>Price</surname><given-names>D</given-names></name><name><surname>Stadlan</surname><given-names>EM</given-names></name></person-group><article-title>Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease</article-title><source>Neurology</source><year>1984</year><volume>34</volume><fpage>939</fpage><lpage>944</lpage><pub-id pub-id-type='pmid'>6610841</pub-id></element-citation></ref><ref id='B9'><label>9</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>McKeith</surname><given-names>IG</given-names></name><name><surname>Dickson</surname><given-names>DW</given-names></name><name><surname>Lowe</surname><given-names>J</given-names></name><name><surname>Emre</surname><given-names>M</given-names></name><name><surname>O'Brien</surname><given-names>JT</given-names></name><name><surname>Feldman</surname><given-names>H</given-names></name><etal></etal></person-group><article-title>Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium</article-title><source>Neurology</source><year>2005</year><volume>65</volume><fpage>1863</fpage><lpage>1872</lpage><pub-id pub-id-type='pmid'>16237129</pub-id></element-citation></ref><ref id='B10'><label>10</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Reisberg</surname><given-names>B</given-names></name></person-group><article-title>Functional assessment staging (FAST)</article-title><source>Psychopharmacol Bull</source><year>1988</year><volume>24</volume><fpage>653</fpage><lpage>659</lpage><pub-id pub-id-type='pmid'>3249767</pub-id></element-citation></ref><ref id='B11'><label>11</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Reisberg</surname><given-names>B</given-names></name><name><surname>Doody</surname><given-names>R</given-names></name><name><surname>Stöffler</surname><given-names>A</given-names></name><name><surname>Schmitt</surname><given-names>F</given-names></name><name><surname>Ferris</surname><given-names>S</given-names></name><name><surname>Möbius</surname><given-names>HJ</given-names></name><collab>Memantine Study Group</collab></person-group><article-title>Memantine in moderate-to-severe Alzheimer's disease</article-title><source>N Engl J Med</source><year>2003</year><volume>348</volume><fpage>1333</fpage><lpage>1341</lpage><pub-id pub-id-type='pmid'>12672860</pub-id></element-citation></ref><ref id='B12'><label>12</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Cummings</surname><given-names>JL</given-names></name><name><surname>Mega</surname><given-names>M</given-names></name><name><surname>Gray</surname><given-names>K</given-names></name><name><surname>Rosenberg-Thompson</surname><given-names>S</given-names></name><name><surname>Carusi</surname><given-names>DA</given-names></name><name><surname>Gornbein</surname><given-names>J</given-names></name></person-group><article-title>The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia</article-title><source>Neurology</source><year>1994</year><volume>44</volume><fpage>2308</fpage><lpage>2314</lpage><pub-id pub-id-type='pmid'>7991117</pub-id></element-citation></ref><ref id='B13'><label>13</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Rothman</surname><given-names>KJ</given-names></name></person-group><article-title>No adjustments are needed for multiple comparisons</article-title><source>Epidemiology</source><year>1990</year><volume>1</volume><fpage>43</fpage><lpage>46</lpage><pub-id pub-id-type='pmid'>2081237</pub-id></element-citation></ref><ref id='B14'><label>14</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Wahlund</surname><given-names>LO</given-names></name><name><surname>Barkhof</surname><given-names>F</given-names></name><name><surname>Fazekas</surname><given-names>F</given-names></name><name><surname>Bronge</surname><given-names>L</given-names></name><name><surname>Augustin</surname><given-names>M</given-names></name><name><surname>Sjögren</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>A new rating scale for age-related white matter changes applicable to MRI and CT</article-title><source>Stroke</source><year>2001</year><volume>32</volume><fpage>1318</fpage><lpage>1322</lpage><pub-id pub-id-type='pmid'>11387493</pub-id></element-citation></ref><ref id='B15'><label>15</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Suh</surname><given-names>DC</given-names></name><name><surname>Thomas</surname><given-names>SK</given-names></name><name><surname>Valiyeva</surname><given-names>E</given-names></name><name><surname>Arcona</surname><given-names>S</given-names></name><name><surname>Vo</surname><given-names>L</given-names></name></person-group><article-title>Drug persistency of two cholinesterase inhibitors: rivastigmine versus donepezil in elderly patients with Alzheimer's disease</article-title><source>Drugs Aging</source><year>2005</year><volume>22</volume><fpage>695</fpage><lpage>707</lpage><pub-id pub-id-type='pmid'>16060719</pub-id></element-citation></ref><ref id='B16'><label>16</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Gauthier</surname><given-names>S</given-names></name><name><surname>Emre</surname><given-names>M</given-names></name><name><surname>Farlow</surname></name><name><surname>Bullock</surname><given-names>R</given-names></name><name><surname>Grossberg</surname><given-names>GT</given-names></name><name><surname>Potkin</surname><given-names>SG</given-names></name></person-group><article-title>Strategies for continued successful treatment of Alzheimer's disease: switching cholinesterase inhibitors</article-title><source>Curr Med Res Opin</source><year>2003</year><volume>19</volume><fpage>707</fpage><lpage>714</lpage><pub-id pub-id-type='pmid'>14687441</pub-id></element-citation></ref><ref id='B17'><label>17</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Massoud</surname><given-names>F</given-names></name><name><surname>Desmarais</surname><given-names>JE</given-names></name><name><surname>Gauthier</surname><given-names>S</given-names></name></person-group><article-title>Switching cholinesterase inhibitors in older adults with dementia</article-title><source>Int Psychogeriatr</source><year>2011</year><volume>23</volume><fpage>372</fpage><lpage>378</lpage><pub-id pub-id-type='pmid'>21044399</pub-id></element-citation></ref><ref id='B18'><label>18</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Wallin</surname><given-names>AK</given-names></name><name><surname>Hansson</surname><given-names>O</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>Londos</surname><given-names>E</given-names></name><name><surname>Minthon</surname><given-names>L</given-names></name></person-group><article-title>Can CSF biomarkers or pre-treatment progression rate predict response to cholinesterase inhibitor treatment in Alzheimer's disease?</article-title><source>Int J Geriatr Psychiatry</source><year>2009</year><volume>24</volume><fpage>638</fpage><lpage>647</lpage><pub-id pub-id-type='pmid'>19123199</pub-id></element-citation></ref></ref-list></back><floats-group><fig orientation='portrait' id='F1' position='float'><label>Fig. 1</label><caption><p>Cognitive, functional, and behavioural evolution in the three study groups. * p = 0.014 (cognitive performance, 4 years) and p = 0.027 (behaviour disturbance, 3 years) (repeated measures analysis of covariance, baseline score as reference). #BPSD = Number of BPSD; FAST = Functional Assessment Staging Scale [<xref rid='B10' ref-type='bibr'>10</xref>].</p></caption><graphic xlink:href='dee-0003-0048-g01'></graphic></fig><fig orientation='portrait' id='F2' position='float'><label>Fig. 2</label><caption><p>Cognitive, functional, and behavioural evolution in the subsample of patients who experienced some adverse event with the first prescribed ChEI. * p = 0.005 (cognitive performance, 4 years) and p = 0.007 (cognitive performance, 5 years) (repeated measures analysis of covariance, baseline score as reference). #BPSD = Number of BPSD; FAST = Functional Assessment Staging Scale [<xref rid='B10' ref-type='bibr'>10</xref>].</p></caption><graphic xlink:href='dee-0003-0048-g02'></graphic></fig><fig orientation='portrait' id='F3' position='float'><label>Fig. 3</label><caption><p>Cognitive, functional, and behavioural evolution in the subsample of patients who did not perceive a positive effect with the first prescribed ChEI. * p = 0.025 (functional dependence, 1 year) and p = 0.044 (behavioural disturbance, 3 years) (repeated measures analysis of covariance, baseline score as reference). #BPSD = Number of BPSD; FAST = Functional Assessment Staging Scale [<xref rid='B10' ref-type='bibr'>10</xref>].</p></caption><graphic xlink:href='dee-0003-0048-g03'></graphic></fig><table-wrap orientation='portrait' id='T1' position='float'><label>Table 1</label><caption><p>Patient attrition in the three study groups</p></caption><table rules='groups' frame='hsides'><thead><tr valign='top'><th colspan='1' rowspan='1'></th><th colspan='1' rowspan='1' align='left'>Persisted on first prescribed ChEI (n = 152)</th><th colspan='1' rowspan='1' align='left'>Changed to other ChEI (n = 36)</th><th colspan='1' rowspan='1' align='left'>Abandoned ChEI treatment (n = 52)</th><th colspan='1' rowspan='1' align='left'>p<xref rid='T1F2' ref-type='table-fn'><sup>2</sup></xref></th></tr></thead><tbody><tr valign='top'><td colspan='1' rowspan='1' align='left'>1-year follow-up visit</td><td colspan='1' rowspan='1'></td><td colspan='1' rowspan='1'></td><td colspan='1' rowspan='1'></td><td colspan='1' rowspan='1'></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'> Died</td><td colspan='1' rowspan='1' char='.' align='char'>0</td><td colspan='1' rowspan='1' char='.' align='char'>0</td><td colspan='1' rowspan='1' char='.' align='char'>0</td><td colspan='1' rowspan='1' align='left'>NA</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'> Lost visit</td><td colspan='1' rowspan='1' char='.' align='char'>0</td><td colspan='1' rowspan='1' char='.' align='char'>0</td><td colspan='1' rowspan='1' char='.' align='char'>0</td><td colspan='1' rowspan='1' align='left'>NA</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'> Died or lost visit</td><td colspan='1' rowspan='1' char='.' align='char'>0</td><td colspan='1' rowspan='1' char='.' align='char'>0</td><td colspan='1' rowspan='1' char='.' align='char'>0</td><td colspan='1' rowspan='1' align='left'>NA</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>2-year follow-up visit</td><td colspan='1' rowspan='1'></td><td colspan='1' rowspan='1'></td><td colspan='1' rowspan='1'></td><td colspan='1' rowspan='1'></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'> Died<xref rid='T1F1' ref-type='table-fn'><sup>1</sup></xref></td><td colspan='1' rowspan='1' char='.' align='char'>0</td><td colspan='1' rowspan='1' char='.' align='char'>0</td><td colspan='1' rowspan='1' char='.' align='char'>0</td><td colspan='1' rowspan='1' align='left'>NA</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'> Lost visit</td><td colspan='1' rowspan='1' char='.' align='char'>8 (5.3)</td><td colspan='1' rowspan='1' char='.' align='char'>0</td><td colspan='1' rowspan='1' char='.' align='char'>2 (3.8)</td><td colspan='1' rowspan='1' char='.' align='char'>0.361</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'> Died or lost visit</td><td colspan='1' rowspan='1' char='.' align='char'>8 (5.3)</td><td colspan='1' rowspan='1' char='.' align='char'>0</td><td colspan='1' rowspan='1' char='.' align='char'>2 (3.8)</td><td colspan='1' rowspan='1' char='.' align='char'>0.361</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>3-year follow-up visit</td><td colspan='1' rowspan='1'></td><td colspan='1' rowspan='1'></td><td colspan='1' rowspan='1'></td><td colspan='1' rowspan='1'></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'> Died<xref rid='T1F1' ref-type='table-fn'><sup>1</sup></xref></td><td colspan='1' rowspan='1' char='.' align='char'>5 (4.0)</td><td colspan='1' rowspan='1' char='.' align='char'>1 (3.2)</td><td colspan='1' rowspan='1' char='.' align='char'>2 (4.2)</td><td colspan='1' rowspan='1' char='.' align='char'>0.976</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'> Lost visit</td><td colspan='1' rowspan='1' char='.' align='char'>27 (17.8)</td><td colspan='1' rowspan='1' char='.' align='char'>5 (13.9)</td><td colspan='1' rowspan='1' char='.' align='char'>6 (11.5)</td><td colspan='1' rowspan='1' char='.' align='char'>0.536</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'> Died or lost visit</td><td colspan='1' rowspan='1' char='.' align='char'>32 (21.1)</td><td colspan='1' rowspan='1' char='.' align='char'>6 (16.7)</td><td colspan='1' rowspan='1' char='.' align='char'>8 (15.4)</td><td colspan='1' rowspan='1' char='.' align='char'>0.614</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>4-year follow-up visit</td><td colspan='1' rowspan='1'></td><td colspan='1' rowspan='1'></td><td colspan='1' rowspan='1'></td><td colspan='1' rowspan='1'></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'> Died<xref rid='T1F1' ref-type='table-fn'><sup>1</sup></xref></td><td colspan='1' rowspan='1' char='.' align='char'>10 (9.0)</td><td colspan='1' rowspan='1' char='.' align='char'>1 (3.8)</td><td colspan='1' rowspan='1' char='.' align='char'>3 (7.0)</td><td colspan='1' rowspan='1' char='.' align='char'>0.659</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'> Lost visit</td><td colspan='1' rowspan='1' char='.' align='char'>43 (28.3)</td><td colspan='1' rowspan='1' char='.' align='char'>10 (27.8)</td><td colspan='1' rowspan='1' char='.' align='char'>12 (23.1)</td><td colspan='1' rowspan='1' char='.' align='char'>0.762</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'> Died or lost visit</td><td colspan='1' rowspan='1' char='.' align='char'>53 (34.9)</td><td colspan='1' rowspan='1' char='.' align='char'>11 (30.6)</td><td colspan='1' rowspan='1' char='.' align='char'>15 (28.8)</td><td colspan='1' rowspan='1' char='.' align='char'>0.690</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>5-year follow-up visit</td><td colspan='1' rowspan='1'></td><td colspan='1' rowspan='1'></td><td colspan='1' rowspan='1'></td><td colspan='1' rowspan='1'></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'> Died<xref rid='T1F1' ref-type='table-fn'><sup>1</sup></xref></td><td colspan='1' rowspan='1' char='.' align='char'>17 (16.7)</td><td colspan='1' rowspan='1' char='.' align='char'>1 (4.2)</td><td colspan='1' rowspan='1' char='.' align='char'>7 (20.0)</td><td colspan='1' rowspan='1' char='.' align='char'>0.224</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'> Lost visit</td><td colspan='1' rowspan='1' char='.' align='char'>50 (32.9)</td><td colspan='1' rowspan='1' char='.' align='char'>12 (33.3)</td><td colspan='1' rowspan='1' char='.' align='char'>17 (32.7)</td><td colspan='1' rowspan='1' char='.' align='char'>0.998</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'> Died or lost visit</td><td colspan='1' rowspan='1' char='.' align='char'>67 (44.1)</td><td colspan='1' rowspan='1' char='.' align='char'>13 (36.1)</td><td colspan='1' rowspan='1' char='.' align='char'>24 (46.2)</td><td colspan='1' rowspan='1' char='.' align='char'>0.616</td></tr></tbody></table><table-wrap-foot><fn><p>Values represent n (%).</p></fn></table-wrap-foot><table-wrap-foot><fn id='T1F1'><label>1</label><p>Percentages calculated on the basis of patients for whom information of mortality was available (mortality information could be obtained for 7 patients with otherwise lost visits).</p></fn><fn id='T1F2'><label>2</label><p>χ<sup>2</sup> test.</p></fn></table-wrap-foot></table-wrap><table-wrap orientation='portrait' id='T2' position='float'><label>Table 2</label><caption><p>Patient and caregiver characteristics by ChEI persistence</p></caption><table rules='groups' frame='hsides'><thead><tr valign='top'><th colspan='1' rowspan='1'></th><th colspan='1' rowspan='1' align='left'>Persisted on first prescribed ChEI (n = 152)</th><th colspan='1' rowspan='1' align='left'>Changed to other ChEI (n = 36)</th><th colspan='1' rowspan='1' align='left'>Abandoned ChEI treatment (n = 52)</th><th colspan='1' rowspan='1' align='left'>p<xref rid='T2F1' ref-type='table-fn'><sup>1</sup></xref></th></tr></thead><tbody><tr valign='top'><td colspan='1' rowspan='1' align='left'>Age, years</td><td colspan='1' rowspan='1' char='.' align='char'>77.1 (6.5)</td><td colspan='1' rowspan='1' char='.' align='char'>74.8 (7.2)<sup>a</sup></td><td colspan='1' rowspan='1' char='.' align='char'>79.1 (5.7)<sup>a</sup></td><td colspan='1' rowspan='1' char='.' align='char'>0.008</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>Females, %</td><td colspan='1' rowspan='1' char='.' align='char'>63.8</td><td colspan='1' rowspan='1' char='.' align='char'>63.9</td><td colspan='1' rowspan='1' char='.' align='char'>73.1</td><td colspan='1' rowspan='1' char='.' align='char'>0.461</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>Education, %</td><td colspan='1' rowspan='1'></td><td colspan='1' rowspan='1'></td><td colspan='1' rowspan='1'></td><td colspan='1' rowspan='1' char='.' align='char'>0.566</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'> Illiterate</td><td colspan='1' rowspan='1' char='.' align='char'>16.7</td><td colspan='1' rowspan='1' char='.' align='char'>14.3</td><td colspan='1' rowspan='1' char='.' align='char'>15.4</td><td colspan='1' rowspan='1'></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'> Primary (incomplete)</td><td colspan='1' rowspan='1' char='.' align='char'>49.3</td><td colspan='1' rowspan='1' char='.' align='char'>34.3</td><td colspan='1' rowspan='1' char='.' align='char'>42.3</td><td colspan='1' rowspan='1'></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'> Primary (complete)</td><td colspan='1' rowspan='1' char='.' align='char'>31.3</td><td colspan='1' rowspan='1' char='.' align='char'>45.7</td><td colspan='1' rowspan='1' char='.' align='char'>36.5</td><td colspan='1' rowspan='1'></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'> Superior education</td><td colspan='1' rowspan='1' char='.' align='char'>2.7</td><td colspan='1' rowspan='1' char='.' align='char'>5.7</td><td colspan='1' rowspan='1' char='.' align='char'>5.8</td><td colspan='1' rowspan='1'></td></tr><tr valign='top'><td colspan='5' rowspan='1' align='left'><hr></hr></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>Hypertension, %</td><td colspan='1' rowspan='1' char='.' align='char'>54.6</td><td colspan='1' rowspan='1' char='.' align='char'>52.8</td><td colspan='1' rowspan='1' char='.' align='char'>46.2</td><td colspan='1' rowspan='1' char='.' align='char'>0.574</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>Diabetes, %</td><td colspan='1' rowspan='1' char='.' align='char'>23.0</td><td colspan='1' rowspan='1' char='.' align='char'>27.8</td><td colspan='1' rowspan='1' char='.' align='char'>25.0</td><td colspan='1' rowspan='1' char='.' align='char'>0.825</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>Dyslipaemia, %</td><td colspan='1' rowspan='1' char='.' align='char'>57.2</td><td colspan='1' rowspan='1' char='.' align='char'>52.8</td><td colspan='1' rowspan='1' char='.' align='char'>59.6</td><td colspan='1' rowspan='1' char='.' align='char'>0.815</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>Ischaemic cardiopathy, %</td><td colspan='1' rowspan='1' char='.' align='char'>6.6</td><td colspan='1' rowspan='1' char='.' align='char'>8.3</td><td colspan='1' rowspan='1' char='.' align='char'>7.7</td><td colspan='1' rowspan='1' char='.' align='char'>0.917</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>Cerebrovascular episode</td><td colspan='1' rowspan='1' char='.' align='char'>10.5</td><td colspan='1' rowspan='1' char='.' align='char'>11.1</td><td colspan='1' rowspan='1' char='.' align='char'>7.7</td><td colspan='1' rowspan='1' char='.' align='char'>0.817</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>Ever smoker, %</td><td colspan='1' rowspan='1' char='.' align='char'>25.8</td><td colspan='1' rowspan='1' char='.' align='char'>27.8</td><td colspan='1' rowspan='1' char='.' align='char'>23.1</td><td colspan='1' rowspan='1' char='.' align='char'>0.875</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>Rosen Scale</td><td colspan='1' rowspan='1' char='.' align='char'>1.1 (1.3)</td><td colspan='1' rowspan='1' char='.' align='char'>1.1 (1.3)</td><td colspan='1' rowspan='1' char='.' align='char'>1.2 (1.7)</td><td colspan='1' rowspan='1' char='.' align='char'>0.951</td></tr><tr valign='top'><td colspan='5' rowspan='1' align='left'><hr></hr></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>Chronic diseases<xref rid='T2F2' ref-type='table-fn'><sup>2</sup></xref>, n</td><td colspan='1' rowspan='1' char='.' align='char'>2.6 (1.7)</td><td colspan='1' rowspan='1' char='.' align='char'>2.2 (1.5)</td><td colspan='1' rowspan='1' char='.' align='char'>3.0 (1.6)</td><td colspan='1' rowspan='1' char='.' align='char'>0.067</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>Medications<xref rid='T2F2' ref-type='table-fn'><sup>2</sup></xref>, n</td><td colspan='1' rowspan='1' char='.' align='char'>3.1 (2.3)</td><td colspan='1' rowspan='1' char='.' align='char'>2.8 (2.0)</td><td colspan='1' rowspan='1' char='.' align='char'>3.0 (2.2)</td><td colspan='1' rowspan='1' char='.' align='char'>0.806</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>On antidepressants, %</td><td colspan='1' rowspan='1' char='.' align='char'>21.7</td><td colspan='1' rowspan='1' char='.' align='char'>38.9</td><td colspan='1' rowspan='1' char='.' align='char'>11.5</td><td colspan='1' rowspan='1' char='.' align='char'>0.010</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>On neuroleptics, %</td><td colspan='1' rowspan='1' char='.' align='char'>6.0</td><td colspan='1' rowspan='1' char='.' align='char'>5.6</td><td colspan='1' rowspan='1' char='.' align='char'>5.8</td><td colspan='1' rowspan='1' char='.' align='char'>0.995</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>On anxiolytics/hypnotics, %</td><td colspan='1' rowspan='1' char='.' align='char'>22.5</td><td colspan='1' rowspan='1' char='.' align='char'>22.2</td><td colspan='1' rowspan='1' char='.' align='char'>15.4</td><td colspan='1' rowspan='1' char='.' align='char'>0.540</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>On other medications for BPSD, %</td><td colspan='1' rowspan='1' char='.' align='char'>2.8</td><td colspan='1' rowspan='1' char='.' align='char'>2.8</td><td colspan='1' rowspan='1' char='.' align='char'>3.8</td><td colspan='1' rowspan='1' char='.' align='char'>0.756</td></tr><tr valign='top'><td colspan='5' rowspan='1' align='left'><hr></hr></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>Disease duration, years</td><td colspan='1' rowspan='1' char='.' align='char'>2.6 (2.2)</td><td colspan='1' rowspan='1' char='.' align='char'>2.4 (1.9)</td><td colspan='1' rowspan='1' char='.' align='char'>2.2 (1.8)</td><td colspan='1' rowspan='1' char='.' align='char'>0.412</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>MMSE</td><td colspan='1' rowspan='1' char='.' align='char'>17.3 (5.0)</td><td colspan='1' rowspan='1' char='.' align='char'>17.1 (4.4)</td><td colspan='1' rowspan='1' char='.' align='char'>16.2 (4.9)</td><td colspan='1' rowspan='1' char='.' align='char'>0.356</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>FAST</td><td colspan='1' rowspan='1' char='.' align='char'>4.1 (0.9)</td><td colspan='1' rowspan='1' char='.' align='char'>3.9 (1.3)</td><td colspan='1' rowspan='1' char='.' align='char'>4.1 (0.9)</td><td colspan='1' rowspan='1' char='.' align='char'>0.670</td></tr><tr valign='top'><td colspan='5' rowspan='1' align='left'><hr></hr></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'><italic>#BPSD</italic></td><td colspan='1' rowspan='1' char='.' align='char'>1.7 (1.5)</td><td colspan='1' rowspan='1' char='.' align='char'>1.8 (1.7)</td><td colspan='1' rowspan='1' char='.' align='char'>1.5 (1.5)</td><td colspan='1' rowspan='1' char='.' align='char'>0.704</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>Delusions, %</td><td colspan='1' rowspan='1' char='.' align='char'>16.4</td><td colspan='1' rowspan='1' char='.' align='char'>13.9</td><td colspan='1' rowspan='1' char='.' align='char'>13.5</td><td colspan='1' rowspan='1' char='.' align='char'>0.843</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>Hallucinations, %</td><td colspan='1' rowspan='1' char='.' align='char'>6.6</td><td colspan='1' rowspan='1' char='.' align='char'>13.9</td><td colspan='1' rowspan='1' char='.' align='char'>5.8</td><td colspan='1' rowspan='1' char='.' align='char'>0.282</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>Aggressive behaviour, %</td><td colspan='1' rowspan='1' char='.' align='char'>17.8</td><td colspan='1' rowspan='1' char='.' align='char'>22.2</td><td colspan='1' rowspan='1' char='.' align='char'>19.2</td><td colspan='1' rowspan='1' char='.' align='char'>0.823</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>Dysphoria, %</td><td colspan='1' rowspan='1' char='.' align='char'>38.2</td><td colspan='1' rowspan='1' char='.' align='char'>41.7</td><td colspan='1' rowspan='1' char='.' align='char'>28.8</td><td colspan='1' rowspan='1' char='.' align='char'>0.386</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>Anxiety, %</td><td colspan='1' rowspan='1' char='.' align='char'>21.7</td><td colspan='1' rowspan='1' char='.' align='char'>25.0</td><td colspan='1' rowspan='1' char='.' align='char'>26.9</td><td colspan='1' rowspan='1' char='.' align='char'>0.721</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>Euphoria, %</td><td colspan='1' rowspan='1' char='.' align='char'>0.0</td><td colspan='1' rowspan='1' char='.' align='char'>0.0</td><td colspan='1' rowspan='1' char='.' align='char'>0.0</td><td colspan='1' rowspan='1' align='left'>NA</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>Apathy, %</td><td colspan='1' rowspan='1' char='.' align='char'>16.4</td><td colspan='1' rowspan='1' char='.' align='char'>19.4</td><td colspan='1' rowspan='1' char='.' align='char'>9.6</td><td colspan='1' rowspan='1' char='.' align='char'>0.384</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>Disinhibition, %</td><td colspan='1' rowspan='1' char='.' align='char'>3.3</td><td colspan='1' rowspan='1' char='.' align='char'>8.3</td><td colspan='1' rowspan='1' char='.' align='char'>3.8</td><td colspan='1' rowspan='1' char='.' align='char'>0.392</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>Irritability, %</td><td colspan='1' rowspan='1' char='.' align='char'>30.9</td><td colspan='1' rowspan='1' char='.' align='char'>16.7</td><td colspan='1' rowspan='1' char='.' align='char'>19.2</td><td colspan='1' rowspan='1' char='.' align='char'>0.093</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>Motor hyperactivity, %</td><td colspan='1' rowspan='1' char='.' align='char'>4.6</td><td colspan='1' rowspan='1' char='.' align='char'>2.8</td><td colspan='1' rowspan='1' char='.' align='char'>3.8</td><td colspan='1' rowspan='1' char='.' align='char'>0.878</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>Sleep disorder, %</td><td colspan='1' rowspan='1' char='.' align='char'>11.8</td><td colspan='1' rowspan='1' char='.' align='char'>13.9</td><td colspan='1' rowspan='1' char='.' align='char'>19.2</td><td colspan='1' rowspan='1' char='.' align='char'>0.410</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>Appetite and eating, %</td><td colspan='1' rowspan='1' char='.' align='char'>2.6</td><td colspan='1' rowspan='1' char='.' align='char'>2.8</td><td colspan='1' rowspan='1' char='.' align='char'>3.8</td><td colspan='1' rowspan='1' char='.' align='char'>0.903</td></tr><tr valign='top'><td colspan='5' rowspan='1' align='left'><hr></hr></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'><italic>Leukoaraiosis<xref rid='T2F3' ref-type='table-fn'><sup>3</sup></xref>, %</italic></td><td colspan='1' rowspan='1'></td><td colspan='1' rowspan='1'></td><td colspan='1' rowspan='1'></td><td colspan='1' rowspan='1' char='.' align='char'>0.050</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>No</td><td colspan='1' rowspan='1' char='.' align='char'>70.0</td><td colspan='1' rowspan='1' char='.' align='char'>88.9</td><td colspan='1' rowspan='1' char='.' align='char'>82.0</td><td colspan='1' rowspan='1'></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>Mild</td><td colspan='1' rowspan='1' char='.' align='char'>2.7</td><td colspan='1' rowspan='1' char='.' align='char'>5.6</td><td colspan='1' rowspan='1' char='.' align='char'>6.0</td><td colspan='1' rowspan='1'></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>Moderate</td><td colspan='1' rowspan='1' char='.' align='char'>25.3</td><td colspan='1' rowspan='1' char='.' align='char'>5.6</td><td colspan='1' rowspan='1' char='.' align='char'>10.0</td><td colspan='1' rowspan='1'></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>Intense</td><td colspan='1' rowspan='1' char='.' align='char'>2.0</td><td colspan='1' rowspan='1' char='.' align='char'>0.0</td><td colspan='1' rowspan='1' char='.' align='char'>2.0</td><td colspan='1' rowspan='1'></td></tr><tr valign='top'><td colspan='5' rowspan='1' align='left'><hr></hr></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'><italic>Aetiology, %</italic></td><td colspan='1' rowspan='1'></td><td colspan='1' rowspan='1'></td><td colspan='1' rowspan='1'></td><td colspan='1' rowspan='1' char='.' align='char'>0.320</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>Probable AD</td><td colspan='1' rowspan='1' char='.' align='char'>52.6</td><td colspan='1' rowspan='1' char='.' align='char'>55.6</td><td colspan='1' rowspan='1' char='.' align='char'>51.9</td><td colspan='1' rowspan='1'></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>Possible AD</td><td colspan='1' rowspan='1' char='.' align='char'>3.9</td><td colspan='1' rowspan='1' char='.' align='char'>8.3</td><td colspan='1' rowspan='1' char='.' align='char'>7.7</td><td colspan='1' rowspan='1'></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>AD with vascular component</td><td colspan='1' rowspan='1' char='.' align='char'>33.6</td><td colspan='1' rowspan='1' char='.' align='char'>16.7</td><td colspan='1' rowspan='1' char='.' align='char'>26.9</td><td colspan='1' rowspan='1'></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>Lewy body disease</td><td colspan='1' rowspan='1' char='.' align='char'>9.9</td><td colspan='1' rowspan='1' char='.' align='char'>19.4</td><td colspan='1' rowspan='1' char='.' align='char'>13.5</td><td colspan='1' rowspan='1'></td></tr><tr valign='top'><td colspan='5' rowspan='1' align='left'><hr></hr></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'><italic>CDR, %</italic></td><td colspan='1' rowspan='1'></td><td colspan='1' rowspan='1'></td><td colspan='1' rowspan='1'></td><td colspan='1' rowspan='1' char='.' align='char'>0.080</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>Very mild dementia (CDR 0.5)</td><td colspan='1' rowspan='1' char='.' align='char'>17.8</td><td colspan='1' rowspan='1' char='.' align='char'>41.7</td><td colspan='1' rowspan='1' char='.' align='char'>17.3</td><td colspan='1' rowspan='1'></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>Mild dementia (CDR 1)</td><td colspan='1' rowspan='1' char='.' align='char'>72.4</td><td colspan='1' rowspan='1' char='.' align='char'>50.0</td><td colspan='1' rowspan='1' char='.' align='char'>73.1</td><td colspan='1' rowspan='1'></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>Moderate dementia (CDR 2)</td><td colspan='1' rowspan='1' char='.' align='char'>8.6</td><td colspan='1' rowspan='1' char='.' align='char'>5.6</td><td colspan='1' rowspan='1' char='.' align='char'>7.7</td><td colspan='1' rowspan='1'></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>Severe dementia (CDR 3)</td><td colspan='1' rowspan='1' char='.' align='char'>1.3</td><td colspan='1' rowspan='1' char='.' align='char'>2.8</td><td colspan='1' rowspan='1' char='.' align='char'>1.9</td><td colspan='1' rowspan='1'></td></tr><tr valign='top'><td colspan='5' rowspan='1' align='left'><hr></hr></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'><italic>Caregiver characteristics, %</italic></td><td colspan='1' rowspan='1'></td><td colspan='1' rowspan='1'></td><td colspan='1' rowspan='1'></td><td colspan='1' rowspan='1'></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>Females</td><td colspan='1' rowspan='1' char='.' align='char'>72.2</td><td colspan='1' rowspan='1' char='.' align='char'>69.4</td><td colspan='1' rowspan='1' char='.' align='char'>63.5</td><td colspan='1' rowspan='1' char='.' align='char'>0.496</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>Relationship</td><td colspan='1' rowspan='1'></td><td colspan='1' rowspan='1'></td><td colspan='1' rowspan='1'></td><td colspan='1' rowspan='1' char='.' align='char'>0.097</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'> Spouse</td><td colspan='1' rowspan='1' char='.' align='char'>41.7</td><td colspan='1' rowspan='1' char='.' align='char'>47.2</td><td colspan='1' rowspan='1' char='.' align='char'>32.7</td><td colspan='1' rowspan='1'></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'> Son or daughter</td><td colspan='1' rowspan='1' char='.' align='char'>52.3</td><td colspan='1' rowspan='1' char='.' align='char'>36.1</td><td colspan='1' rowspan='1' char='.' align='char'>53.8</td><td colspan='1' rowspan='1'></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'> Other</td><td colspan='1' rowspan='1' char='.' align='char'>6.0</td><td colspan='1' rowspan='1' char='.' align='char'>16.7</td><td colspan='1' rowspan='1' char='.' align='char'>13.5</td><td colspan='1' rowspan='1'></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>Lived with the patient</td><td colspan='1' rowspan='1' char='.' align='char'>66.0</td><td colspan='1' rowspan='1' char='.' align='char'>77.8</td><td colspan='1' rowspan='1' char='.' align='char'>67.3</td><td colspan='1' rowspan='1' char='.' align='char'>0.392</td></tr><tr valign='top'><td colspan='5' rowspan='1' align='left'><hr></hr></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'><italic>First prescribed ChEI, %</italic></td><td colspan='1' rowspan='1'></td><td colspan='1' rowspan='1'></td><td colspan='1' rowspan='1'></td><td colspan='1' rowspan='1' char='.' align='char'>0.124</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>Donepezil</td><td colspan='1' rowspan='1' char='.' align='char'>52.0</td><td colspan='1' rowspan='1' char='.' align='char'>41.7</td><td colspan='1' rowspan='1' char='.' align='char'>46.2</td><td colspan='1' rowspan='1'></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>Rivastigmine</td><td colspan='1' rowspan='1' char='.' align='char'>20.4</td><td colspan='1' rowspan='1' char='.' align='char'>16.7</td><td colspan='1' rowspan='1' char='.' align='char'>32.7</td><td colspan='1' rowspan='1'></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>Galantamine</td><td colspan='1' rowspan='1' char='.' align='char'>27.6</td><td colspan='1' rowspan='1' char='.' align='char'>41.7</td><td colspan='1' rowspan='1' char='.' align='char'>21.2</td><td colspan='1' rowspan='1'></td></tr></tbody></table><table-wrap-foot><fn><p>Values represent means (SD), unless % is indicated. #BPSD = Number of BPSD; FAST = Functional Assessment Staging Scale [<xref rid='B10' ref-type='bibr'>10</xref>].</p></fn></table-wrap-foot><table-wrap-foot><fn id='T2F1'><label>1</label><p>Analysis of variance, global test; between-group differences are represented with superscript letters (p &lt; 0.05, Tukey test).</p></fn><fn id='T2F2'><label>2</label><p>Dementia and ChEI were not included.</p></fn><fn id='T2F3'><label>3</label><p>On CT or MRI, according to [<xref rid='B14' ref-type='bibr'>14</xref>].</p></fn></table-wrap-foot></table-wrap><table-wrap orientation='portrait' id='T3' position='float'><label>Table 3</label><caption><p>Safety, tolerability, perceived effect, and reasons of ChEI withdrawal in the three study groups</p></caption><table rules='groups' frame='hsides'><thead><tr valign='top'><th colspan='1' rowspan='1'></th><th colspan='1' rowspan='1' align='left'>Persisted on first prescribed ChEI (n = 152)</th><th colspan='1' rowspan='1' align='left'>Changed to other ChEI (n = 36)</th><th colspan='1' rowspan='1' align='left'>Abandoned ChEI treatment (n = 52)</th><th colspan='1' rowspan='1' align='left'>p<xref rid='T3F1' ref-type='table-fn'><sup>1</sup></xref></th></tr></thead><tbody><tr valign='top'><td colspan='1' rowspan='1' align='left'>Adverse event</td><td colspan='1' rowspan='1' char='.' align='char'>38.8</td><td colspan='1' rowspan='1' char='.' align='char'>72.2</td><td colspan='1' rowspan='1' char='.' align='char'>86.3</td><td colspan='1' rowspan='1' char='.' align='char'>0.000</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>Serious adverse event</td><td colspan='1' rowspan='1' char='.' align='char'>5.3</td><td colspan='1' rowspan='1' char='.' align='char'>2.8</td><td colspan='1' rowspan='1' char='.' align='char'>13.7</td><td colspan='1' rowspan='1' char='.' align='char'>0.067</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>Perceived effect</td><td colspan='1' rowspan='1'></td><td colspan='1' rowspan='1'></td><td colspan='1' rowspan='1'></td><td colspan='1' rowspan='1' char='.' align='char'>0.000</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'> No</td><td colspan='1' rowspan='1' char='.' align='char'>41.7</td><td colspan='1' rowspan='1' char='.' align='char'>77.8</td><td colspan='1' rowspan='1' char='.' align='char'>74.5</td><td colspan='1' rowspan='1'></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'> Yes, stabilization</td><td colspan='1' rowspan='1' char='.' align='char'>24.5</td><td colspan='1' rowspan='1' char='.' align='char'>13.9</td><td colspan='1' rowspan='1' char='.' align='char'>13.7</td><td colspan='1' rowspan='1'></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'> Yes, improvement</td><td colspan='1' rowspan='1' char='.' align='char'>33.8</td><td colspan='1' rowspan='1' char='.' align='char'>8.3</td><td colspan='1' rowspan='1' char='.' align='char'>11.8</td><td colspan='1' rowspan='1'></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>Reasons for withdrawing first ChEI</td><td colspan='1' rowspan='1'></td><td colspan='1' rowspan='1'></td><td colspan='1' rowspan='1'></td><td colspan='1' rowspan='1' char='.' align='char'>0.142</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'> Adverse event</td><td colspan='1' rowspan='1' align='left'>NA</td><td colspan='1' rowspan='1' char='.' align='char'>55.6</td><td colspan='1' rowspan='1' char='.' align='char'>66.0</td><td colspan='1' rowspan='1'></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'> Lack of efficacy</td><td colspan='1' rowspan='1' align='left'>NA</td><td colspan='1' rowspan='1' char='.' align='char'>36.1</td><td colspan='1' rowspan='1' char='.' align='char'>20.0</td><td colspan='1' rowspan='1'></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'> Adverse event and lack of efficacy</td><td colspan='1' rowspan='1' align='left'>NA</td><td colspan='1' rowspan='1' char='.' align='char'>8.3</td><td colspan='1' rowspan='1' char='.' align='char'>6.0</td><td colspan='1' rowspan='1'></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'> Other reason</td><td colspan='1' rowspan='1' align='left'>NA</td><td colspan='1' rowspan='1' char='.' align='char'>0.0</td><td colspan='1' rowspan='1' char='.' align='char'>8.0</td><td colspan='1' rowspan='1'></td></tr></tbody></table><table-wrap-foot><fn><p>Values represent percentages.</p></fn></table-wrap-foot><table-wrap-foot><fn id='T3F1'><label>1</label><p>χ<sup>2</sup> test.</p></fn></table-wrap-foot></table-wrap></floats-group></article></PAPER>